Archive

HIGHLIGHTS

 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announc[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUT[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investme[...]
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Liste...
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the fu[...]
 
Amarin – a story close to our hearts, Keynote speaker at BioCapital
Keynote speaker CEO John Thero telling this remarkable story on our BioCapital conference last week   When we first encountered Amarin Cor[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference,[...]
 
LSP's portfolio company GTX Medical on Dokters van Morgen
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see L[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser...
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discover[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at [...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11[...]

2019


LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the full report click here.  [...]
Upcoming Event: Biotech update 2019
Biotech Update 2019 Wednesday 26th June, 2019 Kasteel De Wittenburg in Wassenaar, The Netherlands [...]
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approxim [...]
Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares
Capital increase of its share capital by issuing 4,093,367 new shares at a purchase price of EUR 2 per new share Consortium of strategic investors led by Claus Christiansen, founder and chairman of Nordic Bi [...]
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
Multiple Updates from Biclonics® Clinical Trials Expected in 2019   UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company [...]
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
CD137 and PD-L1 bispecific antibody with context-dependent T cell activation   UTRECHT, Netherlands, April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Co [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by LSP and existing investor L[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Atlantic Therapeutics, the Irish medical technology company deve[...]
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approxim[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the full report click here. 
 
Amarin – a story close to our hearts, Keynote speaker at BioCapital
Keynote speaker CEO John Thero telling this remarkable story on our BioCapital conference last week   When we first encountered Amarin Corporation it was a microcap company incorporate in Dublin. Despite the [...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference, BioCapital Europe, in the same month. Having a representative from EM[...]
 
LSP's portfolio company GTX Medical on “Dokters van Morgen”
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]

2019


LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the full report click here.  [...]
Upcoming Event: Biotech update 2019
Biotech Update 2019 Wednesday 26th June, 2019 Kasteel De Wittenburg in Wassenaar, The Netherlands [...]
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approxim [...]
Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares
Capital increase of its share capital by issuing 4,093,367 new shares at a purchase price of EUR 2 per new share Consortium of strategic investors led by Claus Christiansen, founder and chairman of Nordic Bi [...]
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
Multiple Updates from Biclonics® Clinical Trials Expected in 2019   UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company [...]
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
CD137 and PD-L1 bispecific antibody with context-dependent T cell activation   UTRECHT, Netherlands, April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Co [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview